The PTP4A3 inhibitor KVX-053 reduces Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virulence, inflammation, and development of acute lung injury in K18-hACE2 mice

DOI record: { "DOI": "10.1186/s12931-025-03349-9", "ISSN": [ "1465-993X" ], "URL": "http://dx.doi.org/10.1186/s12931-025-03349-9", "alternative-id": [ "3349" ], "article-number": "299", "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "9 April 2025" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "19 August 2025" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "28 October 2025" }, { "group": { "label": "Declarations", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Ethics approval and consent to participate", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "Not applicable." }, { "group": { "label": "Consent for publication", "name": "EthicsHeading" }, "name": "Ethics", "order": 3, "value": "Not applicable." }, { "group": { "label": "Competing interests", "name": "EthicsHeading" }, "name": "Ethics", "order": 4, "value": "John S. Lazo and Elizabeth R. Sharlow are co-inventors of U.S. Patent No. 10,308,663, which describes the chemical synthesis, composition of matter and use of KVX-053 for the treatment of cancer. A provisional US patent application entitled “Composition and methods for treating/preventing lung injury” (Serial No. PCT/US2022/024927) and an European Union patent application (22788973.0) with the same title have been filed with John S. Lazo, Elizabeth R. Sharlow, John D. Catravas, Ruben M.L. Colunga Biancatelli, and Pavel A. Solopov being listed as co-inventors. John S. Lazo and Elizabeth Sharlow are co-founders of KeViRx, Inc, which has licensed the above-mentioned intellectual property from the University of Virginia, University of Pittsburgh, and Old Dominion University for further development." } ], "author": [ { "affiliation": [], "family": "Colunga-Biancatelli", "given": "Ruben M. L.", "sequence": "first" }, { "affiliation": [], "family": "Solopov", "given": "Pavel A.", "sequence": "additional" }, { "affiliation": [], "family": "Woodson", "given": "Caitlin M.", "sequence": "additional" }, { "affiliation": [], "family": "Allen", "given": "Irving Coy", "sequence": "additional" }, { "affiliation": [], "family": "Akhrymuk", "given": "Ivan", "sequence": "additional" }, { "affiliation": [], "family": "Akhrymuk", "given": "Maryna", "sequence": "additional" }, { "affiliation": [], "family": "Heath", "given": "Brittany N.", "sequence": "additional" }, { "affiliation": [], "family": "Ivester", "given": "Hannah M.", "sequence": "additional" }, { "affiliation": [], "family": "Day", "given": "Tierney", "sequence": "additional" }, { "affiliation": [], "family": "Austin", "given": "Dan E.", "sequence": "additional" }, { "affiliation": [], "family": "Kehn-Hall", "given": "Kylene", "sequence": "additional" }, { "affiliation": [], "family": "Lazo", "given": "John S.", "sequence": "additional" }, { "affiliation": [], "family": "Sharlow", "given": "Elizabeth R.", "sequence": "additional" }, { "affiliation": [], "family": "Catravas", "given": "John D.", "sequence": "additional" } ], "container-title": "Respiratory Research", "container-title-short": "Respir Res", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2025, 10, 28 ] ], "date-time": "2025-10-28T13:48:23Z", "timestamp": 1761659303000 }, "deposited": { "date-parts": [ [ 2025, 10, 29 ] ], "date-time": "2025-10-29T01:03:13Z", "timestamp": 1761699793000 }, "funder": [ { "DOI": "10.13039/100000002", "award": [ "CCF22-0064-PS ; R43-HL158409-01A1 ; R43-HL158409-01A1S1 ; R43-HL158409-01A1S2 ;" ], "award-info": [ { "award-number": [ "CCF22-0064-PS ; R43-HL158409-01A1 ; R43-HL158409-01A1S1 ; R43-HL158409-01A1S2 ;" ] } ], "doi-asserted-by": "publisher", "id": [ { "asserted-by": "publisher", "id": "10.13039/100000002", "id-type": "DOI" } ], "name": "National Institutes of Health" }, { "DOI": "10.13039/100000002", "award": [ "CCF22-0064-PS ; R43-HL158409-01A1 ; R43-HL158409-01A1S1 ; R43-HL158409-01A1S2 ;" ], "award-info": [ { "award-number": [ "CCF22-0064-PS ; R43-HL158409-01A1 ; R43-HL158409-01A1S1 ; R43-HL158409-01A1S2 ;" ] } ], "doi-asserted-by": "publisher", "id": [ { "asserted-by": "publisher", "id": "10.13039/100000002", "id-type": "DOI" } ], "name": "National Institutes of Health" }, { "DOI": "10.13039/100000002", "award": [ "CCF22-0064-PS ; R43-HL158409-01A1 ; R43-HL158409-01A1S1 ; R43-HL158409-01A1S2 ;" ], "award-info": [ { "award-number": [ "CCF22-0064-PS ; R43-HL158409-01A1 ; R43-HL158409-01A1S1 ; R43-HL158409-01A1S2 ;" ] } ], "doi-asserted-by": "publisher", "id": [ { "asserted-by": "publisher", "id": "10.13039/100000002", "id-type": "DOI" } ], "name": "National Institutes of Health" } ], "indexed": { "date-parts": [ [ 2026, 1, 12 ] ], "date-time": "2026-01-12T09:12:58Z", "timestamp": 1768209178275, "version": "3.49.0" }, "is-referenced-by-count": 1, "issue": "1", "issued": { "date-parts": [ [ 2025, 10, 28 ] ] }, "journal-issue": { "issue": "1", "published-online": { "date-parts": [ [ 2025, 12 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by-nc-nd/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2025, 10, 28 ] ], "date-time": "2025-10-28T00:00:00Z", "timestamp": 1761609600000 } }, { "URL": "https://creativecommons.org/licenses/by-nc-nd/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2025, 10, 28 ] ], "date-time": "2025-10-28T00:00:00Z", "timestamp": 1761609600000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1186/s12931-025-03349-9.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1186/s12931-025-03349-9/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1186/s12931-025-03349-9.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1186", "published": { "date-parts": [ [ 2025, 10, 28 ] ] }, "published-online": { "date-parts": [ [ 2025, 10, 28 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "key": "3349_CR1", "unstructured": "Hopkins J. Coronavirus resoruce center. https://coronavirus.jhu.edu/map.html" }, { "DOI": "10.1111/jeb.13896", "author": "S Alizon", "doi-asserted-by": "publisher", "first-page": "1867", "issue": "12", "journal-title": "J Evol Biol", "key": "3349_CR2", "unstructured": "Alizon S, Sofonea MT. SARS-CoV-2 virulence evolution: avirulence theory, immunity and trade-offs. J Evol Biol. 2021;34(12):1867–77.", "volume": "34", "year": "2021" }, { "DOI": "10.1007/s42977-023-00159-2", "author": "Á Kun", "doi-asserted-by": "publisher", "first-page": "69", "issue": "1–2", "journal-title": "Biol Futura", "key": "3349_CR3", "unstructured": "Kun Á, et al. Do pathogens always evolve to be less virulent? The virulence-transmission trade-off in light of the COVID-19 pandemic. Biol Futura. 2023;74(1–2):69–80.", "volume": "74", "year": "2023" }, { "DOI": "10.1056/NEJMoa2021436", "author": "P Horby", "doi-asserted-by": "publisher", "first-page": "693", "issue": "8", "journal-title": "N Engl J Med", "key": "3349_CR4", "unstructured": "Horby P, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704.", "volume": "384", "year": "2021" }, { "DOI": "10.1056/NEJMoa2030340", "author": "C Salama", "doi-asserted-by": "publisher", "first-page": "20", "issue": "1", "journal-title": "N Engl J Med", "key": "3349_CR5", "unstructured": "Salama C, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(1):20–30.", "volume": "384", "year": "2021" }, { "DOI": "10.1093/cid/ciac724", "author": "A Bhimraj", "doi-asserted-by": "publisher", "first-page": "e250", "issue": "7", "journal-title": "Clin Infect Dis", "key": "3349_CR6", "unstructured": "Bhimraj A, et al. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19 (September 2022). Clin Infect Dis. 2024;78(7):e250–349.", "volume": "78", "year": "2024" }, { "DOI": "10.12998/wjcc.v11.i10.2168", "author": "J Sun", "doi-asserted-by": "publisher", "first-page": "2168", "issue": "10", "journal-title": "World J Clin Cases", "key": "3349_CR7", "unstructured": "Sun J, et al. Clinical application of SARS-CoV-2 antibody detection and monoclonal antibody therapies against COVID-19. World J Clin Cases. 2023;11(10):2168–80.", "volume": "11", "year": "2023" }, { "DOI": "10.1038/s41579-022-00809-7", "author": "M Cox", "doi-asserted-by": "publisher", "first-page": "112", "issue": "2", "journal-title": "Nat Rev Microbiol", "key": "3349_CR8", "unstructured": "Cox M, et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat Rev Microbiol. 2023;21(2):112–24.", "volume": "21", "year": "2023" }, { "author": "Á Avezum", "first-page": "100243", "journal-title": "Lancet Reg Health–Am", "key": "3349_CR9", "unstructured": "Avezum Á, et al. Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE – Coalition V): a double-blind, multicentre, randomised, controlled trial. Lancet Reg Health–Am. 2022;11:100243.", "volume": "11", "year": "2022" }, { "DOI": "10.1002/rmv.2258", "author": "AM Kamel", "doi-asserted-by": "publisher", "issue": "1", "journal-title": "Rev Med Virol", "key": "3349_CR10", "unstructured": "Kamel AM, et al. Efficacy and safety of azithromycin in Covid-19 patients: a systematic review and meta-analysis of randomized clinical trials. Rev Med Virol. 2022;32(1):e2258.", "volume": "32", "year": "2022" }, { "DOI": "10.1016/S0140-6736(20)32013-4", "author": "PW Horby", "doi-asserted-by": "publisher", "first-page": "1345", "issue": "10259", "journal-title": "Lancet", "key": "3349_CR11", "unstructured": "Horby PW, et al. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345–52.", "volume": "396", "year": "2020" }, { "DOI": "10.3201/eid1011.040797_02", "author": "JW LeDuc", "doi-asserted-by": "publisher", "first-page": "e26", "issue": "11", "journal-title": "Emerg Infect Dis", "key": "3349_CR12", "unstructured": "LeDuc JW, Barry MA. SARS, the first pandemic of the 21st century. Emerg Infect Dis. 2004;10(11):e26.", "volume": "10", "year": "2004" }, { "author": "V Apostolopoulos", "first-page": "264", "issue": "2", "journal-title": "Infez Med", "key": "3349_CR13", "unstructured": "Apostolopoulos V, et al. MERS outbreak in riyadh: A current concern in Saudi Arabia. Infez Med. 2024;32(2):264–6.", "volume": "32", "year": "2024" }, { "DOI": "10.1056/NEJMoa2001017", "author": "N Zhu", "doi-asserted-by": "publisher", "first-page": "727", "issue": "8", "journal-title": "N Engl J Med", "key": "3349_CR14", "unstructured": "Zhu N, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.", "volume": "382", "year": "2020" }, { "DOI": "10.1016/j.ijantimicag.2020.105924", "author": "CC Lai", "doi-asserted-by": "publisher", "issue": "3", "journal-title": "Int J Antimicrob Agents", "key": "3349_CR15", "unstructured": "Lai CC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.", "volume": "55", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)30211-7", "author": "N Chen", "doi-asserted-by": "publisher", "first-page": "507", "issue": "10223", "journal-title": "Lancet", "key": "3349_CR16", "unstructured": "Chen N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.", "volume": "395", "year": "2020" }, { "author": "AL Katzenstein", "first-page": "209", "issue": "1", "journal-title": "Am J Pathol", "key": "3349_CR17", "unstructured": "Katzenstein AL, Bloor CM, Leibow AA. Diffuse alveolar damage–the role of oxygen, shock, and related factors. A review. Am J Pathol. 1976;85(1):209–28.", "volume": "85", "year": "1976" }, { "DOI": "10.1038/s41586-021-03569-1", "author": "JC Melms", "doi-asserted-by": "publisher", "first-page": "114", "issue": "7865", "journal-title": "Nature", "key": "3349_CR18", "unstructured": "Melms JC, et al. A molecular single-cell lung atlas of lethal COVID-19. Nature. 2021;595(7865):114–9.", "volume": "595", "year": "2021" }, { "DOI": "10.1038/s41586-020-03148-w", "author": "RA Grant", "doi-asserted-by": "publisher", "first-page": "635", "issue": "7847", "journal-title": "Nature", "key": "3349_CR19", "unstructured": "Grant RA, et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature. 2021;590(7847):635–41.", "volume": "590", "year": "2021" }, { "DOI": "10.1038/s41590-023-01661-4", "author": "N Huot", "doi-asserted-by": "publisher", "first-page": "2068", "issue": "12", "journal-title": "Nat Immunol", "key": "3349_CR20", "unstructured": "Huot N, et al. SARS-CoV-2 viral persistence in lung alveolar macrophages is controlled by IFN-γ and NK cells. Nat Immunol. 2023;24(12):2068–79.", "volume": "24", "year": "2023" }, { "DOI": "10.1038/s41420-021-00428-w", "author": "AC Ferreira", "doi-asserted-by": "publisher", "first-page": "43", "issue": "1", "journal-title": "Cell Death Discov", "key": "3349_CR21", "unstructured": "Ferreira AC, et al. SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes. Cell Death Discov. 2021;7(1):43.", "volume": "7", "year": "2021" }, { "DOI": "10.1038/s41587-020-0602-4", "author": "RL Chua", "doi-asserted-by": "publisher", "first-page": "970", "issue": "8", "journal-title": "Nat Biotechnol", "key": "3349_CR22", "unstructured": "Chua RL, et al. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. Nat Biotechnol. 2020;38(8):970–9.", "volume": "38", "year": "2020" }, { "DOI": "10.1152/ajplung.00223.2021", "author": "RML Colunga Biancatelli", "doi-asserted-by": "publisher", "first-page": "L477", "issue": "2", "journal-title": "Am J Physiol Lung Cell Mol Physiol", "key": "3349_CR23", "unstructured": "Colunga Biancatelli RML, et al. The SARS-CoV-2 Spike protein subunit S1 induces COVID-19-like acute lung injury in Κ18-hACE2 Transgenic mice and barrier dysfunction in human endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2021;321(2):L477–84.", "volume": "321", "year": "2021" }, { "DOI": "10.1124/jpet.124.002154", "author": "PA Solopov", "doi-asserted-by": "publisher", "journal-title": "J Pharmacol Exp Ther", "key": "3349_CR24", "unstructured": "Solopov PA, et al. KVX-053, a protein tyrosine phosphatase 4A3 inhibitor, ameliorates SARS-CoV-2 spike protein subunit 1 - induced acute lung injury in mice. J Pharmacol Exp Ther. 2024. https://doi.org/10.1124/jpet.124.002154.", "year": "2024" }, { "DOI": "10.1096/fasebj.2022.36.S1.R4649", "author": "RML Colunga Biancatelli", "doi-asserted-by": "publisher", "first-page": "1", "journal-title": "FASEB J", "key": "3349_CR25", "unstructured": "Colunga Biancatelli RML, et al. A protein tyrosine phosphatase 4A3 (PTP4A3) inhibitor prevents and repairs pulmonary endothelial barrier dysfunction and ameliorates acute lung injury provoked by the SARS-CoV-2 Spike protein subunit 1 in k18-hACE2 Transgenic mice. FASEB J. 2022;36:1.", "volume": "36", "year": "2022" }, { "DOI": "10.1016/j.jpet.2024.100045", "author": "P Montuschi", "doi-asserted-by": "publisher", "journal-title": "J Pharmacol Exp Ther", "key": "3349_CR26", "unstructured": "Montuschi P, Adcock IM. Protein tyrosine phosphatase 4A3 inhibition: a new pharmacological strategy for acute lung injury? J Pharmacol Exp Ther. 2025. https://doi.org/10.1016/j.jpet.2024.100045.", "year": "2025" }, { "DOI": "10.1074/jbc.M000453200", "author": "Q Zeng", "doi-asserted-by": "publisher", "first-page": "21444", "issue": "28", "journal-title": "J Biol Chem", "key": "3349_CR27", "unstructured": "Zeng Q, et al. Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and – 3 with the plasma membrane and the early endosome. J Biol Chem. 2000;275(28):21444–52.", "volume": "275", "year": "2000" }, { "DOI": "10.1124/jpet.124.002110", "author": "JS Lazo", "doi-asserted-by": "publisher", "journal-title": "J Pharmacol Exp Ther", "key": "3349_CR28", "unstructured": "Lazo JS, et al. Deletion of PTP4A3 phosphatase in high grade serous ovarian cancer cells decreases tumorigenicity and produces marked changes in intracellular signaling pathways and cytokine release. J Pharmacol Exp Ther. 2024. https://doi.org/10.1124/jpet.124.002110.", "year": "2024" }, { "DOI": "10.1124/jpet.122.001401", "author": "SL John", "doi-asserted-by": "publisher", "journal-title": "J Pharmacol Exp Ther", "key": "3349_CR29", "unstructured": "John SL, et al. Disruption of ovarian cancer STAT3 and p38 signaling with a small molecule inhibitor of PTP4A3 phosphatase. J Pharmacol Exp Ther. 2023. https://doi.org/10.1124/jpet.122.001401.", "year": "2023" }, { "DOI": "10.1016/j.chest.2023.07.2959", "author": "LC Manuel", "doi-asserted-by": "publisher", "first-page": "A4565", "issue": "4", "journal-title": "Chest", "key": "3349_CR30", "unstructured": "Manuel LC, Biancatelli R, et al. KVX-053, A PTP4A3 INHIBITOR, MODULATES THE ENDOCYTIC PATHWAY, EXTRACELLULAR VESICLE UPTAKE, ENDOTHELIAL BARRIER DYSFUNCTION, AND THE DEVELOPMENT OF ARDS IN VITRO AND IN VIVO. Chest. 2023;164(4):A4565–6.", "volume": "164", "year": "2023" }, { "DOI": "10.1038/s41586-021-03570-8", "author": "TM Delorey", "doi-asserted-by": "publisher", "first-page": "107", "issue": "7865", "journal-title": "Nature", "key": "3349_CR31", "unstructured": "Delorey TM, et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature. 2021;595(7865):107–13.", "volume": "595", "year": "2021" }, { "DOI": "10.3390/biom11070969", "author": "JS Lazo", "doi-asserted-by": "publisher", "first-page": "969", "issue": "7", "journal-title": "Biomolecules", "key": "3349_CR32", "unstructured": "Lazo JS, et al. Credentialing and pharmacologically targeting PTP4A3 phosphatase as a molecular target for ovarian cancer. Biomolecules. 2021;11(7):969.", "volume": "11", "year": "2021" }, { "DOI": "10.1016/j.vph.2009.12.009", "author": "JD Catravas", "doi-asserted-by": "publisher", "first-page": "175", "issue": "5–6", "journal-title": "Vascul Pharmacol", "key": "3349_CR33", "unstructured": "Catravas JD, et al. Harvesting, identification and barrier function of human lung microvascular endothelial cells. Vascul Pharmacol. 2010;52(5–6):175–81.", "volume": "52", "year": "2010" }, { "DOI": "10.3791/52065", "author": "A Baer", "doi-asserted-by": "publisher", "journal-title": "JoVE", "key": "3349_CR34", "unstructured": "Baer A, Kehn-Hall K. Viral concentration determination through plaque assays: using traditional and novel overlay systems. JoVE. 2014. https://doi.org/10.3791/52065.", "year": "2014" }, { "DOI": "10.1165/rcmb.2009-0210ST", "author": "G Matute-Bello", "doi-asserted-by": "publisher", "first-page": "725", "issue": "5", "journal-title": "Am J Respir Cell Mol Biol", "key": "3349_CR35", "unstructured": "Matute-Bello G, et al. An official American thoracic society workshop report: features and measurements of experimental acute lung injury in animals. Am J Respir Cell Mol Biol. 2011;44(5):725–38.", "volume": "44", "year": "2011" }, { "DOI": "10.18632/oncotarget.23787", "author": "KE McQueeney", "doi-asserted-by": "publisher", "first-page": "8223", "issue": "9", "journal-title": "Oncotarget", "key": "3349_CR36", "unstructured": "McQueeney KE, et al. Targeting ovarian cancer and endothelium with an allosteric PTP4A3 phosphatase inhibitor. Oncotarget. 2018;9(9):8223–40.", "volume": "9", "year": "2018" }, { "DOI": "10.1038/s41592-022-01447-w", "author": "H Chu", "doi-asserted-by": "publisher", "first-page": "392", "issue": "4", "journal-title": "Nat Methods", "key": "3349_CR37", "unstructured": "Chu H, Chan JF-W, Yuen K-Y. Animal models in SARS-CoV-2 research. Nat Methods. 2022;19(4):392–4.", "volume": "19", "year": "2022" }, { "DOI": "10.1128/JVI.00964-21", "author": "W Dong", "doi-asserted-by": "publisher", "first-page": "e0096421", "issue": "1", "journal-title": "J Virol", "key": "3349_CR38", "unstructured": "Dong W, et al. The K18-Human ACE2 transgenic mouse model recapitulates non-severe and severe COVID-19 in response to an infectious dose of the SARS-CoV-2 virus. J Virol. 2022;96(1):e0096421.", "volume": "96", "year": "2022" }, { "DOI": "10.3390/biom14030342", "author": "H Liu", "doi-asserted-by": "publisher", "journal-title": "Biomolecules", "key": "3349_CR39", "unstructured": "Liu H, et al. Protein tyrosine phosphatase PRL-3: a key player in cancer signaling. Biomolecules. 2024. https://doi.org/10.3390/biom14030342.", "year": "2024" }, { "DOI": "10.1016/j.slasd.2023.02.001", "author": "JS Lazo", "doi-asserted-by": "publisher", "first-page": "249", "issue": "6", "journal-title": "SLAS Discov", "key": "3349_CR40", "unstructured": "Lazo JS, et al. An acute respiratory distress syndrome drug development collaboration stimulated by the Virginia drug discovery consortium. SLAS Discov. 2023;28(6):249–54.", "volume": "28", "year": "2023" }, { "author": "KA Kim", "first-page": "181", "issue": "1–3", "journal-title": "FEBS Lett", "key": "3349_CR41", "unstructured": "Kim KA, et al. Structure of human PRL-3, the phosphatase associated with cancer metastasis. FEBS Lett. 2004;565(1–3):181–7.", "volume": "565", "year": "2004" }, { "DOI": "10.1158/0008-5472.CAN-19-0343", "author": "PSY Chong", "doi-asserted-by": "publisher", "first-page": "4679", "issue": "18", "journal-title": "Cancer Res", "key": "3349_CR42", "unstructured": "Chong PSY, et al. IL6 promotes a STAT3-PRL3 feedforward loop via SHP2 repression in multiple myeloma. Cancer Res. 2019;79(18):4679.", "volume": "79", "year": "2019" }, { "DOI": "10.1016/j.bbrc.2012.11.036", "author": "S Lian", "doi-asserted-by": "publisher", "first-page": "196", "issue": "1", "journal-title": "Biochem Biophys Res Commun", "key": "3349_CR43", "unstructured": "Lian S, et al. PRL-3 activates NF-κB signaling pathway by interacting with RAP1. Biochem Biophys Res Commun. 2013;430(1):196–201.", "volume": "430", "year": "2013" }, { "DOI": "10.1074/jbc.M113.480038", "author": "MW Zimmerman", "doi-asserted-by": "publisher", "first-page": "5904", "issue": "9", "journal-title": "J Biol Chem", "key": "3349_CR44", "unstructured": "Zimmerman MW, et al. Protein-tyrosine phosphatase 4A3 (PTP4A3) promotes vascular endothelial growth factor signaling and enables endothelial cell motility. J Biol Chem. 2014;289(9):5904–13.", "volume": "289", "year": "2014" }, { "DOI": "10.1111/j.1365-2958.2005.04822.x", "author": "H Martín", "doi-asserted-by": "publisher", "first-page": "6", "issue": "1", "journal-title": "Mol Microbiol", "key": "3349_CR45", "unstructured": "Martín H, et al. Protein phosphatases in MAPK signalling: we keep learning from yeast. Mol Microbiol. 2005;58(1):6–16.", "volume": "58", "year": "2005" }, { "DOI": "10.1182/blood.V110.11.671.671", "author": "M Sebag", "doi-asserted-by": "publisher", "first-page": "671", "issue": "11", "journal-title": "Blood", "key": "3349_CR46", "unstructured": "Sebag M, et al. PRL3 is a mediator of IL6/STAT3 signaling and defines a population of multiple myeloma patients distinct from those that activate NFkB. Blood. 2007;110(11):671–671.", "volume": "110", "year": "2007" }, { "DOI": "10.1016/j.freeradbiomed.2021.10.015", "author": "Y Shi", "doi-asserted-by": "publisher", "first-page": "72", "journal-title": "Free Radic Biol Med", "key": "3349_CR47", "unstructured": "Shi Y, et al. PRL-3 dephosphorylates p38 MAPK to promote cell survival under stress. Free Radic Biol Med. 2021;177:72–87.", "volume": "177", "year": "2021" }, { "DOI": "10.1186/1471-2091-13-22", "author": "W Tian", "doi-asserted-by": "publisher", "first-page": "22", "journal-title": "BMC Biochem", "key": "3349_CR48", "unstructured": "Tian W, et al. Phosphatase of regenerating liver-3 directly interacts with integrin β1 and regulates its phosphorylation at tyrosine 783. BMC Biochem. 2012;13:22.", "volume": "13", "year": "2012" }, { "DOI": "10.1038/s41392-022-01038-3", "author": "J Pan", "doi-asserted-by": "publisher", "issue": "1", "journal-title": "Signal Transduct Target Ther", "key": "3349_CR49", "unstructured": "Pan J, et al. Targeting protein phosphatases for the treatment of inflammation-related diseases: from signaling to therapy. Signal Transduct Target Ther. 2022;7(1):177.", "volume": "7", "year": "2022" }, { "DOI": "10.1038/s41598-019-39643-y", "author": "L Duciel", "doi-asserted-by": "publisher", "first-page": "2990", "issue": "1", "journal-title": "Sci Rep", "key": "3349_CR50", "unstructured": "Duciel L, et al. Protein tyrosine phosphatase 4A3 (PTP4A3/PRL-3) promotes the aggressiveness of human uveal melanoma through dephosphorylation of CRMP2. Sci Rep. 2019;9(1):2990.", "volume": "9", "year": "2019" }, { "DOI": "10.1016/j.bmcl.2021.128167", "author": "EJ Rastelli", "doi-asserted-by": "publisher", "journal-title": "Bioorg Med Chem Lett", "key": "3349_CR51", "unstructured": "Rastelli EJ, et al. Synthesis and evaluation of bifunctional PTP4A3 phosphatase inhibitors activating the ER stress pathway. Bioorg Med Chem Lett. 2021;46:128167.", "volume": "46", "year": "2021" }, { "DOI": "10.1124/jpet.119.262188", "author": "JS Lazo", "doi-asserted-by": "publisher", "first-page": "652", "issue": "3", "journal-title": "J Pharmacol Exp Ther", "key": "3349_CR52", "unstructured": "Lazo JS, et al. Next-generation cell-active inhibitors of the undrugged oncogenic PTP4A3 phosphatase. J Pharmacol Exp Ther. 2019;371(3):652–62.", "volume": "371", "year": "2019" }, { "DOI": "10.1124/molpharm.120.000131", "author": "MP Czub", "doi-asserted-by": "publisher", "first-page": "648", "issue": "6", "journal-title": "Mol Pharmacol", "key": "3349_CR53", "unstructured": "Czub MP, et al. Structure of the complex of an iminopyridinedione protein tyrosine phosphatase 4A3 phosphatase inhibitor with human serum albumin. Mol Pharmacol. 2020;98(6):648–57.", "volume": "98", "year": "2020" }, { "DOI": "10.7150/thno.79265", "author": "PL Chia", "doi-asserted-by": "publisher", "first-page": "1876", "issue": "6", "journal-title": "Theranostics", "key": "3349_CR54", "unstructured": "Chia PL, et al. PRL3 as a therapeutic target for novel cancer immunotherapy in multiple cancer types. Theranostics. 2023;13(6):1876–91.", "volume": "13", "year": "2023" }, { "DOI": "10.1124/jpet.124.002154", "author": "PA Solopov", "doi-asserted-by": "publisher", "first-page": "100022", "issue": "3", "journal-title": "J Pharmacol Exp Ther", "key": "3349_CR55", "unstructured": "Solopov PA, et al. KVX-053, a protein tyrosine phosphatase 4A3 inhibitor, ameliorates SARS-CoV-2 Spike protein subunit 1–induced acute lung injury in mice. J Pharmacol Exp Ther. 2025;392(3):100022.", "volume": "392", "year": "2025" }, { "DOI": "10.1038/s41467-025-59929-2", "author": "KH Ang", "doi-asserted-by": "publisher", "first-page": "4791", "issue": "1", "journal-title": "Nat Commun", "key": "3349_CR56", "unstructured": "Ang KH, et al. PRL3-zumab as an anti-angiogenic therapy in neovascular eye diseases. Nat Commun. 2025;16(1):4791.", "volume": "16", "year": "2025" } ], "reference-count": 56, "references-count": 56, "relation": {}, "resource": { "primary": { "URL": "https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-025-03349-9" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "The PTP4A3 inhibitor KVX-053 reduces Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virulence, inflammation, and development of acute lung injury in K18-hACE2 mice", "type": "journal-article", "update-policy": "https://doi.org/10.1007/springer_crossmark_policy", "volume": "26" }